News

The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.

Hatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.

In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.

Nivolumab given with cisplatin-based chemotherapy has received approval from the FDA for patients with treatment-naive unresectable or mUC.

The combination of a novel mTORC1/2 inhibitor with paclitaxel could present a new way of targeting metastatic or persistent endometrial cancer.

Belantamab mafodotin plus pomalidomide and dexamethasone significantly extended progression-free survival in multiple myeloma, offering a potential new treatment option with different mechanisms of action.

Cambritaxestat, a first-in-class therapy in development for highly fibrotic cancer indications that overexpress autotaxin, has been granted an orphan drug designation from the FDA in pancreatic cancer.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, provided an update on developments, unmet needs, and future directions for the treatment of patients with myelofibrosis.

Enfortumab vedotin with pembrolizumab significantly improved survival outcomes compared with chemotherapy in patients with previously untreated advanced urothelial cancer.

The FDA has approved inotuzumab for the treatment of pediatric patients 1 year or older with acute lymphoblastic leukemia.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Third-line combination of THIO and cemiplimab improved overall response rate compared with standard of care in patients with non-small cell lung cancer.

Balancing cost and efficiency remains at the crux of autologous stem cell transplants for multiple myeloma treatment.

The FDA orphan drug designation qualifies the sponsor of avutometinib for tax credits for clinical trials, exemption from user fees, and potential market exclusivity.

In an interview with Targeted Oncology, Chakra Chaulagain, MD, discussed the trends of higher rates of autologous hematopoietic stem cell transplantation refusal among patients with multiple myeloma.

The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.

The investigational new drug application for CLN-619 has been granted clearance from the FDA, marking it as a potential for the treatment of relapsed/refractory multiple myeloma.

The FDA approved the investigational new drug application for olaptesed pegol as a potential treatment for adult patients with aggressive brain cancer, specifically glioblastoma.

For Colorectal Cancer Awareness Month, Jedrzej Wykretowicz, MD, PhD, discussed the importance of early detection and taking steps towards the prevention of colorectal cancer.

The first-in-human study that has received FDA clearance will investigate the novel autologous Innocell vaccine in stage III/IV ovarian cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

The FDA has initiated a rolling submission for mirdametinib, an investigational MEK inhibitor, for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas in pediatric and adult patients.

A recent study identified key risk factors that link with increased symptom burden in patients with endometrial cancer.

The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.

Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.

Following the development of further safety and monitoring protocols, the IOV-LUN-202 trial can resume patient enrollment.

In an interview with Targeted Oncology, Claire Saxton, MBA, and Ashley Moncrief, discussed the importance of education efforts focused on ensuring that patients with MDS understand their diagnosis and options so that they can make informed decisions about their care.

Orca-T therapy boosts survival in elderly with hematologic cancer, while trilaciclib shows promise in triple-negative breast cancer treatment.

Hedyeh Ebrahimi, MD, discussed a novel approach to targeting metastatic renal cell carcinoma through a microbiome-mediated pathway.

In an interview with Targeted Oncology, Matthew Matasar, MD, discussed the advantages and current applications of bispecific antibodies for the treatment of B-cell lymphomas.